Risk of malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis
| Autor: | Xia Wang, Zoe Marjenberg, Ann E. Clarke, Nina Embleton, S. Langham, Nick Pooley, Julia Langham, Volkan Barut, Lindsay Nicholson, Barnabas Desta, Edward R Hammond |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Risk Oncology medicine.medical_specialty Population Malignancy Rheumatology Risk Factors immune system diseases Neoplasms Internal medicine Odds Ratio medicine Humans Lupus Erythematosus Systemic education education.field_of_study business.industry Cancer medicine.disease Comorbidity Confidence interval Lymphoma Anesthesiology and Pain Medicine Meta-analysis Relative risk business |
| Zdroj: | Seminars in Arthritis and Rheumatism. 51:1230-1241 |
| ISSN: | 0049-0172 4201-8110 |
| Popis: | Background Malignancy is a potential comorbidity in patients with systemic lupus erythematosus (SLE). However, risk by malignancy type remains to be fully elucidated. We evaluated the risk of malignancy type in SLE patients in a systematic review and meta-analysis. Methods MEDLINE and EMBASE were searched from inception to July 2018 to identify observational studies that evaluated malignancy risk in adult SLE patients compared with the general population. Random-effects models were used to calculate pooled risk ratios (RRs) and 95% confidence intervals (CIs). Heterogeneity was quantified using the I2 test. Findings Forty-one studies reporting on 40 malignancies (one overall, 39 site-specific) were included in the meta-analysis. The pooled RR for all malignancies from 3694 events across 80 833 patients was 1.18 (95% CI: 1.00-1.38). The risk of 24 site-specific malignancies (62%) was increased in SLE patients. For malignancies with ≥6 studies, non-Hodgkin lymphoma and Hodgkin lymphoma risk was increased >3-fold; myeloma and liver >2-fold; cervical, lung, bladder, and thyroid ≥1.5-fold; stomach and brain >1.3-fold. The risk of four malignancies (breast, uterine, melanoma, prostate) was decreased, whereas risk of 11 other malignancies did not differ between SLE patients and the general population. Heterogeneity ranged between 0% and 96%, and 63% were non-significant. Interpretation The risk of overall and some site-specific malignancies is increased in SLE compared with the general population. However, the risk for some site-specific malignancies is decreased or did not differ. Further examination of risk profiles and SLE patient phenotypes may support guidelines aimed at reducing malignancy risk. Funding AstraZeneca. Systematic review registration PROSPERO number: CRD42018110433. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect